Stock IOLCP IOL CHEMICALS AND PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials IOL Chemicals and Pharmaceuticals Limited NSE India S.E.

Equities

IOLCP

INE485C01011

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 07:43:48 2024-05-03 am EDT 		5-day change 1st Jan Change
395.6 INR +0.83% Intraday chart for IOL Chemicals and Pharmaceuticals Limited -0.99% -14.62%
Mar. 19 IOL Chemicals Gets Zero Observations from Brazilian Health Regulatory Agency After Inspection of Units MT
Feb. 19 IOL Chemicals Gets Nod to Export Diabetes Drug to China MT

Valuation

Fiscal Period: March 2023 2024 2025 2026
Capitalization 1 16,608 23,183 - -
Enterprise Value (EV) 1 16,608 23,183 23,183 23,183
P/E ratio 11.9 x 12.5 x 9.95 x 9.3 x
Yield 1.41% 1.61% 1.8% 1.95%
Capitalization / Revenue 0.75 x 0.97 x 0.87 x 0.82 x
EV / Revenue 0.75 x 0.97 x 0.87 x 0.82 x
EV / EBITDA 7.36 x 7.7 x 6.19 x 5.77 x
EV / FCF -18.5 x 14.4 x 273 x 23.8 x
FCF Yield -5.39% 6.94% 0.37% 4.2%
Price to Book 1.1 x 1.4 x 1.25 x 1.13 x
Nbr of stocks (in thousands) 58,706 58,706 - -
Reference price 2 282.9 394.9 394.9 394.9
Announcement Date 4/28/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2023 2024 2025 2026
Net sales 1 22,171 23,960 26,650 28,405
EBITDA 1 2,257 3,010 3,743 4,020
EBIT 1 2,051 2,540 3,164 3,380
Operating Margin 9.25% 10.6% 11.87% 11.9%
Earnings before Tax (EBT) 1 1,886 2,529 3,152 3,367
Net income 1 1,391 1,857 2,331 2,490
Net margin 6.28% 7.75% 8.75% 8.77%
EPS 2 23.70 31.60 39.70 42.45
Free Cash Flow 1 -895.5 1,610 85 973
FCF margin -4.04% 6.72% 0.32% 3.43%
FCF Conversion (EBITDA) - 53.49% 2.27% 24.2%
FCF Conversion (Net income) - 86.7% 3.65% 39.07%
Dividend per Share 2 4.000 6.350 7.100 7.700
Announcement Date 4/28/23 - - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 5,414 5,235 5,872 5,632 5,982 6,002 6,319
EBITDA 1 - 426.9 953 725.2 849.5 770 778
EBIT - - - - - - -
Operating Margin - - - - - - -
Earnings before Tax (EBT) - - - - - - -
Net income 1 - 237.9 647.8 458.6 547 484 494
Net margin - 4.54% 11.03% 8.14% 9.14% 8.06% 7.82%
EPS - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 11/14/22 2/7/23 4/28/23 8/9/23 - - -
1INR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: March 2023 2024 2025 2026
Net Debt - - - -
Net Cash position - - - -
Leverage (Debt/EBITDA) - - - -
Free Cash Flow 1 -896 1,610 85 973
ROE (net income / shareholders' equity) 9.6% 11.8% 13.3% 12.8%
ROA (Net income/ Total Assets) - - - -
Assets 1 - - - -
Book Value Per Share 2 257.0 282.0 315.0 349.0
Cash Flow per Share - - - -
Capex 1 2,118 2,000 1,975 1,975
Capex / Sales 9.55% 8.35% 7.41% 6.95%
Announcement Date 4/28/23 - - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for IOL Chemicals and Pharmaceuticals Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
394.9 INR
Average target price
517 INR
Spread / Average Target
+30.92%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. IOLCP Stock
  4. IOLCP Stock
  5. Financials IOL Chemicals and Pharmaceuticals Limited